Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy

Autor: Anna Nordenskjöld, Helena Fohlin, Johan Rosell, Nils-Olof Bengtsson, Tommy Fornander, Thomas Hatschek, Henrik Lindman, Per Malmström, Lisa Rydén, Arne Wallgren, Olle Stål, Bo Nordenskjöld

Publikováno v: Breast, Vol 71, Iss , Pp 63-68 (2023)

Background: Tamoxifen is an established treatment for breast cancer, but its long-term effects on survival and on secondary cancers are not fully evaluated. Material and methods: We studied 30 years outcome of 4124 postmenopausal patients who were ra

Externí odkaz: https://doaj.org/article/487528a90ae34cc4bee6e74d37bc5e34

Sex Disparities in

Autor: Anja, Smits, Malgorzata, Lysiak, Andreas, Magnusson, Johan, Rosell, Peter, Söderkvist, Annika, Malmström

Publikováno v: Journal of Clinical Medicine

Introduction: Recent studies suggest an overrepresentation of MGMT promoter methylated tumors in females with IDHwt glioblastoma (GBM) compared to males, with a subsequent better response to alkylating treatment. Methods: To reveal sex-bound associat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::31e901ff81aa6506cba675e9b8c9b799
https://pubmed.ncbi.nlm.nih.gov/33546098

Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer

Autor: Jenny Isaksson, Henrik Gréen, Elisabeth Åvall-Lundqvist, Linn Pettersson, Mats Anden, Nils O. Elander, Dimitrios Papantoniou, Johan Rosell

Publikováno v: World Journal of Clinical Oncology

BACKGROUNDThe majority of patients with newly diagnosed metastatic prostate cancer (PC) initially respond to androgen deprivation therapy (ADT) and are classified as metastatic castration-sensitive PC (mCSPC). Following months to years of ADT, the di

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f164bdf43fed912a52f999c2f350c737
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-181923

Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis

Autor: Malgorzata Lysiak, Peter Söderkvist, Hans Skovgaard Poulsen, Johan Rosell, Annika Malmström, J. Dowsett, Rikke Hedegaard Dahlrot, K. de Stricker, Henning B. Boldt, Steinbjørn Hansen, S. Fosmark, Roger Henriksson, Mia D. Sørensen, Bjarne Winther Kristensen

Publikováno v: Dahlrot, R H, Dowsett, J, Fosmark, S, Malmström, A, Henriksson, R, Boldt, H B, de Stricker, K, Sørensen, M D, Poulsen, H S, Lysiak, M, Söderkvist, P, Rosell, J, Hansen, S & Kristensen, B W 2018, ' Prognostic value of O-6-methylguanine–DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis ', Neuropathology and Applied Neurobiology, vol. 44, no. 2, pp. 172-184 . https://doi.org/10.1111/nan.12415

Aims: It is important to predict response to treatment with temozolomide (TMZ) in glioblastoma (GBM) patients. Both MGMT protein expression and MGMT promoter methylation status have been reported to predict the response to TMZ. We investigated the pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6187a68dafc11e6d750fb45477c1ff6f
https://doi.org/10.1111/nan.12415

Management and outcome of TaG3 tumours of the urinary bladder in the nationwide, population-based bladder cancer database Sweden (BladderBaSe)

Autor: Truls Gårdmark, Viveka Ströck, Fredrik Liedberg, Firas Aljabery, Amir Sherif, Tomas Jerlström, Staffan Jahnson, Abolfazl Hosseini, Lars Holmberg, Johan Rosell, Christel Häggström, Per-Uno Malmström

Publikováno v: Scandinavian journal of urology. 53(4)

Purpose: To investigate the management of TaG3 tumours of the urinary bladder using nationwide population-based data in relation to the prevailing guidelines, patients' characteristics, and outcome ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75420a0c77d23d2ab80f046713006b79
https://pubmed.ncbi.nlm.nih.gov/31144582